| 2017 | A randomized; phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) (vol 8; pg 15943; 2017)
| ONCOTARGET |
| 2017 | Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. | JOURNAL OF CLINICAL ONCOLOGY |
| 2016 | Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer
| CANCER RESEARCH AND TREATMENT |
| 2016 | Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma | HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK |
| 2016 | EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines
| MOLECULAR CANCER THERAPEUTICS |
| 2016 | Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells | APOPTOSIS |
| 2016 | Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
| BMC CANCER |
| 2016 | Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy | PHARMACOGENETICS AND GENOMICS |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck | CLINICAL CANCER RESEARCH |
| 2015 | Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells | CELLULAR SIGNALLING |
| 2015 | Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest | CELLULAR SIGNALLING |
| 2015 | Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.
| ONCOTARGET |
| 2015 | Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
| MOLECULAR CANCER THERAPEUTICS |
| 2015 | An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer | EUROPEAN JOURNAL OF CANCER |
| 2015 | LAMC2 enhances the metastatic potential of lung adenocarcinoma | CELL DEATH AND DIFFERENTIATION |
| 2015 | Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
| ONCOTARGET |
| 2015 | Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication
| PLOS ONE |
| 2015 | The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer | LUNG CANCER |
| 2014 | Establishment of a mouse melanoma model system for the efficient infection and replication of human adenovirus type 5-based oncolytic virus | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS |
| 2014 | Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma | LUNG CANCER |
| 2014 | A prospective phase II trial of s-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2014 | Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma | LUNG CANCER |
| 2014 | Tumor MET expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors | THORACIC CANCER |
| 2014 | Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
| GENOME MEDICINE |
| 2014 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. | LANCET |
| 2014 | Clinical Outcome According to the Level of Preexisting Epidermal Growth Factor Receptor T790M Mutation in Patients With Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations | CANCER |
| 2014 | Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations | LUNG CANCER |
| 2013 | TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically modulated by the Src/CIN85/c-Cbl complex | CELLULAR SIGNALLING |
| 2013 | A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes | ANNALS OF ONCOLOGY |
| 2013 | Transforming growth factor-β gene silencing using adenovirus expressing TGF-β1 or TGF-β2 shRNA | CANCER GENE THERAPY |
| 2013 | c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5 | CANCER GENE THERAPY |
| 2013 | Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2013 | Crosstalk from survival to necrotic death coexists in DU-145 cells by curcumin treatment: Inhibition of apoptosis by caspase degradation. | CELLULAR SIGNALLING |
| 2013 | Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
| SUPPORTIVE CARE IN CANCER |
| 2013 | Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
| YONSEI MEDICAL JOURNAL |
| 2013 | Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer
| YONSEI MEDICAL JOURNAL |
| 2013 | Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation | MOLECULAR CANCER THERAPEUTICS |
| 2013 | S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial
| BMC CANCER |
| 2013 | Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer | BREAST |
| 2013 | The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy | INTERNATIONAL JOURNAL OF ONCOLOGY |
| 2013 | The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma
| YONSEI MEDICAL JOURNAL |
| 2013 | Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer | LUNG CANCER |
| 2013 | The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
| ANNALS OF ONCOLOGY |
| 2013 | Better Outcome of XELOX Chemotherapy in Patients with Advanced Intestinal-Type Adenocarcinoma of the Ampulla of Vater
| TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE |
| 2013 | A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC) | LUNG CANCER |
| 2012 | Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer
| BMC CANCER |
| 2012 | Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
| CANCER |
| 2012 | HSP27 modulates survival signaling networks in cells treated with curcumin and TRAIL. | CELLULAR SIGNALLING |
| 2012 | High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
| CLINICAL CANCER RESEARCH |
| 2012 | Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy
| PLOS ONE |
(Yonsei Health Research Network)
